|
|
03-May-2012
Background
25% of primitive breast cancers overexpress the HER2 oncoreceptor which is a poor...
|
|
03-May-2012
Background
The mTOR pathway is constitutively activated in hormone-resistant ABC. In phase II...
|
|
03-May-2012
Endocrine resistance is a major clinical issue. AP-1 is a transcription factor downstream of...
|
|
24-Apr-2012
Background:
Gastrointestinal stromal tumors (GISTs) and desmoid tumors (DTs) are two rare...
|
|
24-Apr-2012
Background:
AT9283 is an inhibitor of aurora kinases A and B with antitumor activity in...
|
|
24-Apr-2012
Background:
Based on our previous work on the clinical activity of cetuximab in recurrent...
|
|
24-Apr-2012
Background:
It is not known if verum (real) acupuncture is effective for nausea and vomiting...
|
|
24-Apr-2012
Background:
IMM-101 is a heat-killed innate and adaptive immune-activating mycobacterial product;...
|
|
24-Apr-2012
Background:
To contribute to evidence-based policy decision making for national cancer control, we...
|
|
24-Apr-2012
Background:
Hand-foot syndrome (HFS) is the most common adverse event induced by capecitabine....
|
|
